ACE2 and COVID-19: Indeed, a monoclonal antibody against the receptor binding domain (RBD) of SARS‐CoV‐2, obtained from B cells of immunized COVID‐19 patients, has been shown to block the SARS‐CoV‐2 S protein/ACE2 interaction.15